• Please log in or register to access this feature.

ORIGINAL ARTICLE

You have free access to this content

Unidentified Candidates for Cardiac Resynchronization Therapy: Guideline Adherence in a Large Academic Outpatient Clinic in the Netherlands

  1. JORIS R. de GROOT M.D., Ph.D.*,
  2. SÉBASTIEN P. J. KRUL M.D.,
  3. SEM KROON,
  4. REINOUD E. KNOPS M.D.,
  5. RON J. G. PETERS M.D., Ph.D.,
  6. ARTHUR A. M. WILDE M.D., Ph.D.

Article first published online: 18 OCT 2012

DOI: 10.1111/pace.12021

Issue

Pacing and Clinical Electrophysiology

Pacing and Clinical Electrophysiology

Volume 36, Issue 1, pages 69–75, January 2013

Additional Information

How to Cite

de GROOT, J. R., KRUL, S. P. J., KROON, S., KNOPS, R. E., PETERS, R. J. G. and WILDE, A. A. M. (2013), Unidentified Candidates for Cardiac Resynchronization Therapy: Guideline Adherence in a Large Academic Outpatient Clinic in the Netherlands. Pacing and Clinical Electrophysiology, 36: 69–75. doi: 10.1111/pace.12021

Author Information

  1. From the Heart Center, Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands

*Address for reprints: Dr. J. R. de Groot, M.D., Ph.D., Academic Medical Center, Department of Cardiology, PO box 22660, 1100 DD Amsterdam, The Netherlands. Fax: 3120-5669618; e-mail: j.r.degroot@amc.uva.nl

  1. Disclosures: Dr. De Groot is supported by the Netherlands Heart Foundation, grant 2009T021. The authors have no disclosures.

Publication History

  1. Issue published online: 9 JAN 2013
  2. Article first published online: 18 OCT 2012
  3. Manuscript Accepted: 27 AUG 2012
  4. Manuscript Revised: 31 JUL 2012
  5. Manuscript Received: 25 JUN 2012

Funded by

  • Netherlands Heart Foundation. Grant Number: 2009T021

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (535K)

References

  • 1
    Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539–1549.
  • 2
    Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, et al. Cardiac resynchronization in heart failure. N Engl J Med 2001; 346:1845–1853.
  • 3
    Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De MArco T, Carson P, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140–2150.
  • 4
    Moss AJ, Cannom DS, Klein H, Daubert JP, Estes III NA, Greenberg H, Higgins SL, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361:1329–1338.
  • 5
    Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, et al. Combined cardiac resynchronization and implantable cardiovertion defibrillation in advanced chronic heart failure. The MIRACLE ICD Trial. JAMA 2003; 289:2685–2694.
  • 6
    Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connoly S, Hohnloser SH, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363:2385–2395.
  • 7
    Linde C, Abraham WT, Gold MR, St John SM, Ghio S, Daubert C, REVERSE Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008; 52:1834–1843.
  • 8
    Dickstein K, Vardas P, Auricchio A, Daubert JP, Linde C, McMurray J, Ponikowski P, et al. 2010 Focused update of ESC guidelines on device therapy in heart failure. Eur Heart J 2010; 31:2677–2687.
  • 9
    Goldenberg I, Moss AJ, Hall WJ Foster E, Goldenberger JJ, Santucci P, Shinn T, et al. Predictors of response to cardiac resynchronization therapy in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT). Circulation 2011; 124:1527–1536.
  • 10
    Beshai JF, Grimm RA, Nagueh SF, Baker II JH, Beau SL, Greenberg SM, Pires LA, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007; 357:2461–2471.
  • 11
    Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang JC. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: Meta analysis of randomized controlled trials. Arch Intern Med 2011; 171:1454–1462.
  • 12
    Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials. Am Heart J 2012; 163:260–267.
  • 13
    Stevenson WG, Hernandez AF, Carson PE, Fang JC, Katz SD, Spertus JA, Sweitzer NK, et al. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail 2012; 18:94–106.
  • 14
    Hardziyenka M, Surie S, De Groot JR, De Bruin-Bon R, Knops RE, Remmelink M, Yong ZY, et al. Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: An open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension. Europace 2011; 13:1753–1759.
  • 15
    Blomström P, Ekman M, Blomström-Lundqvist C, Calvert CJ, Freemantle N, Lönnerholm S, Wikström G, et al. Cost effectiveness of cardiac resynchronization therapy in the Nordic region: An analysis based on the CARE-HF trial. Eur J Heart Fail 2008; 10:869–877.
  • 16
    Maniadakis N, Ekman M, Calvert MJ, Freemantle N, Karamalis M, Vardas P. Cost effectiveness of cardiac resynchronization therapy in Greese: An analysis based on the CArdiac REsynchronization in Heart Failure trial. Europace 2011; 13:1597–1603.
  • 17
    Linde C, Mealing S, Hawkins N, Eaton J, Brown B, Daubert JC. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure symptoms: Insight from the European cohort of the REVERSE (Resynchronization reverses remodeling in systolic left ventricular dysfunction). Eur Heart J 2011; 32:1631–1639.
  • 18
    Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 2007; 298:1517–1524.
  • 19
    Hernandez AF, Fonarow GC, Liang L, Curtis LH, LaBresh KA, Yancy CW, Albert NM, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 2007; 298:1525–1532.
  • 20
    Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008; 52:1111–1121.
  • 21
    Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51:288–296.
  • 22
    Nakagawa M, Iwao T, Abe H, Ishida S, Takahashi N, Fujino T, Yonemochi H, et al. Influence of autonomic tone on the filtered QRS duration from signal averaged electrocardiograms in healthy volunteers. J Electrocardiol 2000; 33:17–22.
View Full Article (HTML) Get PDF (535K)